Collplant expands rhcollagen-based bioink platform with launch of collink.3d™ 90

Collink.3d™ 90 offers additional functionality to address wide range of 3d bioprinting applications, including soft and hard tissues collink.3d™ 90 demonstrates faster human cell migration into gel matrices compared with a commercial hydrogel widely used for 2d and 3d cell culture second bioink launch advances company's strategic goal to build portfolio of rhcollagen-based bioinks for biopharma and academic customers rehovot, israel , nov. 7, 2022 /prnewswire/ -- collplant (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the company is launching collink.3d™ 90, a recombinant human collagen (rhcollagen)-based bioink for use in a variety of 3d bioprinting applications. collink.3d™ 90 is complementary to the company's first commercial bioink, collink.3d™ 50, which was launched late last year, offering increased mechanical properties to address additional printing requirements of soft and hard tissues.
CLGN Ratings Summary
CLGN Quant Ranking